Cancer Therapy CME/CE Courses

Cancer Therapy CME/CE Courses

myCMEYour search for high-quality, complimentary CME/CE stops right here. The courses below are presented by myCME, the continuing education engine in Haymarket Medical Network’s (HMN) expanding portfolio of clinical websites. Below you’ll find practice-relevant courses that carry valuable CME/CE credit. Simply click any link to get started earning credit on myCME.

Featured Courses

Examining the Clinical Potential of PARP Inhibitors in Prostate Cancer

Examining the Clinical Potential of PARP Inhibitors in Prostate Cancer

AMA PRA Category 1 Credit(s)TM
The advent of poly-(ADP ribose)-polymerase (PARP) inhibitors for a variety of malignancies has led to the evaluation of their use in patients with metastatic castrate resistant prostate cancer (mCRPC), and has the potential to shift treatment paradigms for these patients.
COVID-19 Infections and Hematologic Disturbances

COVID-19 Infections and Hematologic Disturbances

AMA PRA Category 1 Credit(s)TM
This education will provide physicians with the resources necessary to discuss treatment options with patients, payers and administrators to ensure that each stakeholder understands the importance of those options for the management of patients with hematologic malignancies and COVID-19.
RME Hot Seat: Weighing the Clinical Evidence on Treatment Strategies for Myeloma

Treatment Strategies for Myeloma | myCME

AMA PRA Category 1 Credit(s)TM
This RME Hot Seat provides a virtual Q&A with a panel of multiple myeloma (MM) experts who field a range of questions on MM patient care, covering such topics as the use of minimal residual disease (MRD)–driven maintenance approaches, immunotherapy, the use of belantamab mafodotin, cytogenetic risk status, and the value of three-drug and four-drug regimens.
Episode 2: Relating the Pathophysiology of MDS to the Mechanism of Action (MOA) of Novel Agents

Episode 2: Pathophysiology of MDS and the MOA of Novel Agents

AMA PRA Category 1 Credit(s)TM, CE for Pharmacists, CNE Contact Hour(s)
This is the second of 3 episodes in this Oncology Prime Time series which will address diagnosis, risk stratification, and the mechanisms and clinical applications of new and emerging agents in MDS.
A 55-Year-Old Woman With Malignant Pheochromocytoma

A 55-Year-Old Woman With Malignant Pheochromocytoma

AMA PRA Category 1 Credit(s)TM
The goal of this activity is to provide clinicians with a brief review of pheochromocytoma and paraganglioma, its presentation, and the role of targeted therapeutics for metastatic disease.

Click for More Oncology Courses

Next hm-section-front in CME